Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 23;10:1071464. doi: 10.3389/fped.2022.1071464

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Hexner-Erlichman, Veiga-da-Cunha, Zehavi, Vadasz, Sabag, Tatour and Spiegel.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Evolution of 1,5-anhydroglucitol and neutrophils counts in blood before and during empagliflozin (EMPA) treatment for PT1 and PT2. (A) 1,5-AG present in plasma was measured by LC-MS analysis in blood samples from PT1 and PT2 taken before and during treatment. (B,C). The time-line shows that in the case of both patients, following the initiation of EMPA treatment, ANC remain above 1,500 × 10⁶/l (despite the end of GCSF treatment in PT1—panel B) indicating the absence of neutropenia episodes (ANC < 1,500 × 10⁶/l).